OLGA BELOTSERKOVSKAYA: Open Payments
NPI 1144310111 · BESSEMER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$985 in 45 payments from 14 companies in 2025. Trend: 2023 $631 · 2024 $781 · 2025 $985
Food & beverage: $985
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $208 |
| Janssen Pharmaceuticals, Inc | 7 | $139 |
| Axsome Therapeutics, Inc. | 5 | $106 |
| ABBVIE INC. | 4 | $81 |
| E.R. Squibb & Sons, L.L.C. | 4 | $80 |
| ACADIA Pharmaceuticals Inc | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Alkermes, Inc. | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $30 |
Products named: CAPLYTA, INVEGA SUSTENNA, VRAYLAR, COBENFY, NUPLAZID, ARISTADA, Sunosi, Auvelity.
Industry payments across AL — which companies pay providers there.
